Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biosyent Inc (TSE:RX)
:RX
Holding TSE:RX?
Track your performance easily
Earnings Data
Report Date
Mar 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.15Last Year’s EPS
0.12Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 21, 2018
|% Change Since: 0.18%
|Next Earnings Date:Aug 22, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, consistent profitability, dividend increases, and new product developments, overshadowing the slight decline in cash position.Company Guidance
During the Q2 2024 earnings call for BioSyent Inc., CEO René Goehrum highlighted several key financial metrics and strategic initiatives. The company's Canadian pharmaceutical business experienced an 11% revenue increase in the quarter compared to the previous year, with a 14% rise over six months. Overall, quarterly revenues reached just under $9 million, marking a 12% year-over-year growth, while EBITDA exceeded $2 million, and net income after tax was nearly $1.6 million. On a six-month basis, sales rose by 15%, EBITDA by 26%, and net income after tax also increased by 26%, with EBITDA and NIAT margins at 25% and 20%, respectively. The quarter marked the 56th consecutive profitable period for BioSyent, with trailing 12-month earnings per share at $0.60 fully diluted. The company declared a Q3 dividend of $0.045 and highlighted a 1.5% reduction in outstanding shares through share repurchases. Additionally, BioSyent announced a new endocrinology product for a 2026 launch and continued growth in products such as FeraMAX, Tibella, Inofolic, and Gelclair, while maintaining a strong cash position of just under $26 million as of June 30, 2024. The call emphasized strategic investments in growth, portfolio diversification, and shareholder returns, including a 21% return on equity and nearly $23 million returned to shareholders through dividends and share buybacks.Record-Breaking Revenue and Growth
Revenues were just under $9 million for the quarter, up 12% compared to the previous year and up 15% on a 6-month basis. This represents a record quarter in revenue for BioSyent Inc.
Consistent Profitability
The second quarter marked BioSyent Inc.'s 56th consecutive profitable quarter, with EBITDA exceeding $2 million and net income after tax just under $1.6 million.
Strong Dividend Growth
Quarterly dividends in March and June increased by 12.5% compared to the previous year. A Q3 dividend of $0.045 was announced for September 15.
New Product Developments
BioSyent announced the in-licensing of a new endocrinology product for Canada, expected to launch in 2026, indicating future growth potential.
Successful Share Buyback Program
BioSyent repurchased 162,300 shares under NCIB, reducing outstanding shares by roughly 1.5%.
Recognition and Awards
FeraMAX was named the #1 recommended oral iron supplement for the ninth consecutive year, and BioSyent was included in the TSX Venture 50 top-performing companies.
---
TSE:RX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSE:RX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 20, 2024 | C$10.87 | C$11.26 | +3.59% |
| Aug 26, 2024 | C$10.13 | C$10.51 | +3.75% |
| May 16, 2024 | C$8.39 | C$8.88 | +5.84% |
| Mar 13, 2024 | C$8.54 | C$8.50 | -0.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Biosyent Inc (TSE:RX) report earnings?
Biosyent Inc (TSE:RX) is schdueled to report earning on Mar 19, 2025, TBA Not Confirmed.
What is Biosyent Inc (TSE:RX) earnings time?
Biosyent Inc (TSE:RX) earnings time is at Mar 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:RX EPS forecast?
TSE:RX EPS forecast for the fiscal quarter 2024 (Q4) is 0.15.
---